

Inocucor Technologies Inc. announces first close of C\$38.8M Series B financing led by TPG Art

Date closed: 3/28/2017

Value: C\$38.8 billion

On March 28, 2017, Inocucor Technologies Inc. (Inocucor) announced completion of the C\$38.8 million first close of its Series B financing round. The lead investor in the first close is TPG Alternative and Renewable Technologies (TPG ART), a growth-equity and late-stage venture capital vehicle of global alternative asset firm TPG. Other participants in this first Series B round are Cycle Capital Management, the Montreal-based clean tech venture capital firm that made its first investment in Inocucor in late 2013; Desjardins Innovatech, another original investor and the venture capital group of Desjardins, one of Canada's leading cooperative financial groups with more than \$200 billion in assets; and Closed Loop Capital, an early-stage venture capital fund investing in agriculture technologies and food system innovations

Inocucor, headquartered in Montreal, Quebec, is a producer of sustainable biological crop inputs.

BLG represented Cycle Capital Management and Desjardins with a team led by <u>Patrice Martin</u> that included <u>Calvin Leung</u>, <u>Patricia Galella</u> and <u>Stefan Timms</u>.

For more information, please contact:

Tamara Costa

National Director, Marketing and Communications Borden Ladner Gervais LLP <u>TCosta@blg.com</u> 416.350.2642



BLG | Canada's Law Firm

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 725 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

blg.com

© 2025 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.